Welcome to our dedicated page for MNK news (Ticker: MNK), a resource for investors and traders seeking the latest updates and insights on MNK stock.
The MNK news page on Stock Titan aggregates company-issued updates and media coverage related to Mallinckrodt plc and its subsequent branded therapeutics identity, Keenova Therapeutics. Recent press releases describe Mallinckrodt as a global specialty pharmaceutical company with a Brands business focused on autoimmune and rare diseases and a Par Health business that includes generic drugs, sterile injectables and active pharmaceutical ingredients.
News items for MNK include announcements on corporate transactions, such as the completion of the merger between Mallinckrodt and Endo, Inc., and the spin-off of the combined generics and sterile injectables businesses under the Par Health name. These releases also explain that, moving ahead, Mallinckrodt will be known as Keenova Therapeutics, a branded therapeutics company focused on helping patients with rare or unaddressed conditions.
Investors and followers of MNK can find updates on financial results, including quarterly net sales and segment performance for Specialty Brands, Generics and Sterile Injectables as reported by the company. Other news covers developments in key branded products, such as Acthar Gel and XIAFLEX, as well as communications about clinical and medical affairs activities, including data presentations related to TERLIVAZ for hepatorenal syndrome.
Additional coverage includes leadership and governance announcements, such as board appointments and executive changes, along with guidance and commentary on the company’s strategy around its Brands and Par Health businesses. For users tracking MNK, this news feed provides a central view of the company’s own disclosures on its therapeutic focus, portfolio evolution, corporate structure and branded transition to Keenova Therapeutics.
Mallinckrodt plc (NYSE: MNK) announced that the FDA issued a Complete Response Letter (CRL) for its New Drug Application (NDA) of terlipressin, intended to treat hepatorenal syndrome type 1 (HRS-1). The FDA stated that more data is needed to demonstrate a positive risk-benefit profile for terlipressin, which currently lacks FDA approval despite being used as standard care in other countries. HRS-1 affects 30,000 to 40,000 Americans annually, with a high mortality rate if untreated. Mallinckrodt remains committed to pursuing FDA approval, despite expressing disappointment with the CRL's issuance.
Mallinckrodt Pharmaceuticals (NYSE: MNK) announced its Specialty Generics business received two Manufacturing Leadership Awards from the National Association of Manufacturers. The Hobart, N.Y. manufacturing site won awards in Operational Excellence Leadership for a packaging changeover project that cut time by 50%, and in Engineering and Production Technology Leadership for exceeding FDA serialization requirements. This is the third consecutive year of recognition, underscoring the company's commitment to quality manufacturing solutions.
Mallinckrodt plc (NYSE: MNK) announced that the FDA accepted the Biologics License Application for StrataGraft skin tissue, an investigational therapy for adults with deep partial-thickness thermal burns. The FDA granted priority review, setting a PDUFA target date of February 2, 2021. The therapy aims to reduce the need for autografting, which is currently the standard care. Approximately 40,000 patients in the U.S. are hospitalized annually for severe burns. The development is supported by BARDA as part of a public health initiative.
In Q2 2020, Mallinckrodt reported net sales of $166.5 million and adjusted net sales of $700.9 million, a 14.9% decline primarily due to COVID-19 impacts and competitive pressures. The diluted loss per share stood at $11.04, while adjusted diluted EPS was $1.89, down 25.3%. The company reported cash flow from operations of $170.9 million and free cash flow of $159.5 million. Additionally, they face potential Chapter 11 reorganization due to ongoing opioid litigation and high debt levels. Despite challenges, pipeline advancements include FDA advisory committee support for terlipressin.
Mallinckrodt plc (NYSE: MNK) announced that the FDA's Cardiovascular and Renal Drugs Advisory Committee voted 8 to 7 in favor of recommending approval for terlipressin to treat hepatorenal syndrome type 1 (HRS-1), a severe condition linked to acute kidney failure in cirrhosis patients. There are currently no approved therapies for HRS-1 in the U.S., affecting 30,000 to 40,000 Americans annually. The FDA has set a PDUFA target date of September 12, 2020, for the New Drug Application review, following promising results from the Phase 3 CONFIRM trial.
Mallinckrodt (NYSE: MNK) is set to announce its second quarter 2020 earnings results on August 4, 2020, for the period ending June 26, 2020.
The conference call for investors will begin at 8:30 a.m. Eastern Time, with access available through their website, telephone, or audio replay. Investors can expect insights into the company's performance in areas like autoimmune and rare diseases, as well as specialty pharmaceuticals.
Mallinckrodt plc (NYSE: MNK) announced that the FDA's Cardiovascular and Renal Drugs Advisory Committee will hold a virtual meeting to review its New Drug Application (NDA) for terlipressin. This investigational drug targets hepatorenal syndrome type 1 (HRS-1), a severe condition with high mortality rates and no approved therapies in the U.S. The NDA is supported by data from the Phase 3 CONFIRM trial, the largest study of its kind for HRS-1, involving 300 patients. If approved, terlipressin could meet a critical medical need for approximately 30,000 to 40,000 annual patients in the U.S.
Mallinckrodt plc (NYSE: MNK), a biopharmaceutical company, will present at the BMO Prescriptions for Success Healthcare Conference on June 23, 2020, at 8:00 a.m. Eastern Time. CEO Mark Trudeau and CFO Bryan Reasons will engage in a fireside chat during the event. Investors can access the webcast via the company's investor relations page. A replay will be available post-conference. Mallinckrodt specializes in treating autoimmune and rare diseases, focusing on various therapeutic areas. For more details, visit www.mallinckrodt.com/investors.
Mallinckrodt plc (NYSE: MNK) expressed disappointment following the U.S. Court of Appeals' denial of its request for a temporary injunction against the CMS regarding Medicaid drug rebate calculations for Acthar® Gel. The court's decision requires a change to the average manufacturer price, leading to estimated retroactive charges of $650 million and risking annual net sales of $90 to $100 million from Acthar. Mallinckrodt plans to appeal and believes the District Court misinterpreted relevant statutes.
Mallinckrodt plc (NYSE: MNK) announced the presentation of data from the Phase 3 trial (STRATA2016) of its investigational product, StrataGraft®, at the virtual American Burn Association's 52nd Annual Meeting. The trial evaluates StrataGraft as a regenerative skin tissue therapy for deep partial-thickness thermal burns. Preliminary results will be shared by Dr. James H. Holmes, IV. StrataGraft aims to reduce the need for autografting, addressing significant limitations in current treatment methods. Regulatory approval by the FDA is pending, with StrataGraft having orphan drug status.